EXPEDITING TIME TO TRIAL FOR COVID-19
PATIENT RESPIRATORY TREATMENT
At the Meary Center for Cell and Gene Therapy in France, directed by Professor Jérôme Larghero, Dr. Guillaume Churlaud and his team are contributing to a treatment for COVID-19 patients now in a clinical trial [Sept. 2020]. Their cell production expertise was essential for the development of this cell therapy.
Working with several teams within Assistance Publique– Hôpitaux de Paris (AP-HP), they aim to treat intubated-ventilated patients with severe acute respiratory syndrome caused by coronavirus (SARS Cov2).
The treatment consists of three intravenous administrations of mesenchymal stromal cells (MSCs), repeated every 48 hours. They hope that this treatment will alleviate the patients’ respiratory symptoms and improve their medical state.
“Since this clinical trial was set up so quickly, everything had to be done fast, including validation of the cell counting method for MSCs using the NucleoCounter® NC-200™”, says Dr. Guillaume Churlaud, when asked which challenges his team faced in this COVID-19 trial.
“Before, our cell counting and viability were determined by manual cell counting, using a counting chamber [hemacytometer] and trypan blue. The method was fast, but we saw variable data depending on the operator. We also used a flow cytometer, which was reproducible but a more time-consuming method.”
Learn more about the Meary Center at: www.centremeary.aphp.fr
The NucleoCounter® NC-200™ provides a fast, reproducible, and repeatable method of cell counting between operators. In our hands, we found that it was easy to use and we only needed a short training session on the device before we could start using it. The pros of this automated cell counter are definitely the robust and fast data acquisition and having 21 CFR Part 11-compliant software. It is well worth the upgrade from manual cell counting as it expedites our path to the clinic for this treatment.
Dr. Guillaume Churlaud, Meary Center for Cell and Gene Therapy
We support COVID-19 treatments
Read the full story of AdaptVac’s work to develop a vaccine for the corona virus, using their VLP-technology. Or learn more about how our NucleoCounter® instruments can support you in developing a cell therapy for COVID-19 or other diseases.
We also provide online information, expert support, and instrument demos on how to use our instruments in your lab. Check out our webinar series on challenges and considerations in cell counting and learn more about how we can support your COVID-19 research.
“At ChemoMetec, we support researchers who work to develop vaccines for the COVID-19 pandemic. We provided a NucleoCounter® NC-202™ automated cell counter and Via2-Cassette™ consumables to AdaptVac so they no longer have to do time-consuming manual cell counting. This releases critical staff resources to focus on vaccine development, so AdaptVac can reach their goals faster. We are very proud to support one of Europe’s top teams in the fight against COVID-19! ”
Steen Søndergaard, CEO of ChemoMetec.